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Edited by Varda RotterAbstract Mdm2, a RING-ﬁnger type ubiquitin ligase, is over-
expressed in a variety of human cancers. It promotes ubiquitina-
tion of the tumor suppressor p53 and can function as an oncogene
by largely downregulating p53. Recently, we reported that
Mdm2 degrades retinoblastoma tumor suppressor protein
(pRB) via the ubiquitin–proteasome system. In the present study,
we assessed the eﬀects of MdmX, a structural homolog of
Mdm2, on the Mdm2-mediated ubiquitination of pRB. MdmX
is known to negatively regulate p53 function by enhancing the
Mdm2-mediated ubiquitination and degradation of p53. Interest-
ingly, MdmX inhibited the Mdm2-mediated pRB ubiquitination.
Furthermore, an MdmX siRNA decreased the endogenous pRB
level, while MdmX overexpression stimulated pRB functions in
cultured cells. Therefore, MdmX may have diﬀerent roles in
the regulation of Mdm2 activity for ubiquitination of pRB and
p53.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The RB gene, located on chromosome 13q14.2, is a major
tumor-suppressor gene that encodes the approximately 110-
kDa nuclear phosphoprotein retinoblastoma protein (pRB).
pRB plays a role in controlling G1 phase and cell proliferation
[1]. In late G1 phase, pRB is mainly regulated via phosphory-
lation by the cyclin D1/cyclin-dependent kinase 4/6 complex
[2–4]. It is known that inactivation of p16ink4 or enhanced deg-
radation of p27Kip1 activates G1 cyclin-Cdk kinases and in-
duces the inactivation of pRB in some types of human
tumors. In regard to abnormalities in the RB gene, deletion
of the RB gene and altered expression of pRB have been ob-
served in several human cancers [5]. In addition to these re-
ports, we previously showed that Mdm2, a RING-ﬁnger type
ubiquitin ligase for p53 protein, facilitated ubiquitination of
pRB and promoted its degradation via the ubiquitin–protea-
some pathway [6]. It has been recently reported that Mdm2
can promote proteasome-dependent ubiquitin-independentAbbreviation: pRB, retinoblastoma protein
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ubiquitination of p53 and its subsequent degradation by the
proteasome [8], thereby functioning as an oncogene largely
by regulating the level of p53. Enhanced expression of
Mdm2 also accelerates pRB degradation, indicating that
Mdm2 is involved in abrogation of the RB-tumor suppressor
pathway as well as the p53 pathway.
MdmX is a structural homolog of Mdm2 that binds to p53
via the N-terminal domains of both MdmX and p53 [9,10].
MdmX and Mdm2 form a heterodimeric complex via the
RING-ﬁnger domains located at their C-terminal ends [11].
Although MdmX lacks detectable E3 ubiquitin ligase activity
in cells and is unable to degrade p53 by itself [12], formation
of the Mdm2–MdmX complex stimulates the E3 ubiquitin li-
gase activity of Mdm2 and Mdm2-mediated ubiquitination
and degradation of p53 [13,14]. In addition, MdmX can inhibit
p53 transcriptional activity and this inhibition is dependent on
the p53-binding domain of MdmX [9]. Thus, MdmX is a neg-
ative regulator of p53, and functions as a positive cofactor of
Mdm2 and an inhibitor of p53-dependent transcription.
Given the important role of Mdm2 in the regulation of pRB
functions, we investigated whether MdmX also has an eﬀect on
the Mdm2 activity for pRB ubiquitination. In the present
study, we found that MdmX binds to pRB and inhibits
Mdm2-mediated pRB ubiquitination and downregulation.2. Materials and methods
2.1. Plasmids
The pcDNA4/HisMax-wild-type Mdm2, pcDNA4/HisMax-full-
length pRB, pcDNA4/HisMax-RB-RI, pCGN-HA-ubiquitin, and
FLAG-p53 plasmids were described in our previous report [6].
pcDNA3.1-4 · FLAG-Mdm2 was generated by subcloning the
Mdm2 cDNA into a pcDNA3.1 vector containing a 4· FLAG-tag se-
quence. A human MdmX cDNA was generated by PCR and cloned
into pBluescript II+. The SalI–BamHI fragment of the MdmX cDNA
was then subcloned into pcDNA3.1 containing a 3· FLAG-tag
sequence to construct a 3· FLAG-MdmX plasmid. A 3· FLAG-
MdmXDC plasmid was generated by removing the XcmI–ApaI
fragment from the 3· FLAG-MdmX plasmid. The C/EBPb-luciferase
plasmid was a gift from Hayashi.2.2. Antibodies
Anti-FLAG (M2) antibody was purchased from Promega. Anti-p53
(DO-1), anti-Mdm2 (SMP14), anti-MdmX (D-19) and Omni-probe
(M-21) antibodies were purchased from Santa Cruz. Anti-pRB (G3-
245) and anti-Hsp90 antibodies were obtained from BD Pharmingen.
MdmX monoclonal antibodies 3G12 and 7C8 were previously
described [15].blished by Elsevier B.V. All rights reserved.
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The cell line SRB1 is a pRB-inducible clone of Saos2 cells regulated
by tetracycline (Tet-oﬀ system) [16]. SRB1-wt-Mdm2 cells were estab-
lished by transfection of pcDNA4/HisMax-wild-type (wt)-Mdm2 into
SRB1 cells, followed by cloning using zeocin. SRB1-wt-Mdm2 cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum (FBS), 0.5 mg/ml of G418, 0.3 mg/ml
of hygromycin, 1 lg/ml of tetracycline and 0.3 mg/ml of zeocin.
p53/ Mdm2/ mouse embryonic ﬁbroblasts (MEFs) were cultured
in DMEM supplemented with 10% FBS, non-essential amino acids
and sodium pyruvate. HEK293 cells, HCT116 cells and U2OS cells
were cultured in DMEM containing 10% FBS. HEK293 cells were
transfected using the calcium phosphate method, while SRB1-wt-
Mdm2 cells and HCT116 cells were transfected using the FuGENE 6
reagent (Roche Molecular Biochemicals).
2.4. RNAi
U2OS cells in 6 cm plates were maintained in DMEM containing
10% FBS. Prior to transfection, the culture medium was changed to
OptiMEM-I (GIBCO BRL). A total of 600 pmol of siRNA/dish
(200 nM) was transfected using Oligofectamine (Invitrogen) as the
transfection agent. An equal volume of DMEM containing 20% FBS
was added to the plates at 6 h after the transfection. After a further
18 h, the medium was replaced with DMEM containing 10% FBS
and the culture was continued for another 24 h. The sense sequenceFig. 1. Mdm2-mediated ubiquitination of pRB is inhibited by MdmX. (A)
mutant. (B) Enhancement of Mdm2-mediated ubiquitination of p53 by Mdm
Expression plasmids for the indicated proteins were transfected into HCT116
previously [6]. Ubiquitinated p53 was detected by immunoblotting (IB) with
with the indicated antibodies, SMP14 and D-19, respectively. Ubiquitinated p
antibody (G3-245).of the human MdmX siRNA was as follows: 5 0-AACUGCCG-
CUUUUGAAGAUtt-3 0. A negative control siRNA was purchased
from QIAGEN.3. Results
3.1. MdmX inhibits Mdm2-mediated pRB ubiquitination
Since Mdm2 promotes the ubiquitin-dependent degradation
of pRB as demonstrated in our previous study [6], we were
interested in whether MdmX inﬂuences the Mdm2-mediated
downregulation of pRB. MdmX is a p53-binding protein that
is structurally homologous to Mdm2 (Fig. 1A). Although
MdmX itself does not promote p53 ubiquitination and degra-
dation, it has been shown to stimulate Mdm2-mediated ubiq-
uitination and degradation of p53 [14]. Thus, we supposed
that Mdm2-mediated pRB ubiquitination would also be en-
hanced by MdmX. To investigate the eﬀect of MdmX on
Mdm2-mediated ubiquitination of p53 and pRB under our
experimental conditions, we performed in vivo ubiquitination
assays using various expression plasmids (Fig. 1B and C). AsSchematic representations of pRB, Mdm2, MdmX and the MdmXDC
X. (C) Inhibition of Mdm2-mediated ubiquitination of pRB by MdmX.
cells. In vivo ubiquitination experiments were performed as described
an anti-p53 antibody (DO-1). Mdm2 and MdmX were analyzed by IB
RB was detected by immunoprecipitation (IP) and IB with an anti-pRB
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both Mdm2 and MdmX were transiently overexpressed
(Fig. 1B, lane 4), although the Mdm2-dependent ubiquitina-
tion was moderate (Fig. 1B, lane 3) under this experimental
condition. MdmXDC, which hardly bound to Mdm2 (data
not shown; [11]) due to its lack of the RING-ﬁnger domain re-
quired for heterodimerization with Mdm2 (Fig. 1A), did not
enhance the Mdm2-mediated ubiquitination of p53 (Fig. 1B,
lane 5). Strikingly, however, MdmX reduced the Mdm2-med-
itated pRB ubiquitination (Fig. 1C, compare lane 3 with lane
4), and MdmXDC retained this ability to inhibit the pRB ubiq-
uitination (Fig. 1C, lane 5). These results indicate that MdmX
possesses diﬀerent activities in the regulation of the Mdm2-
mediated ubiquitination of p53 and pRB.
3.2. MdmX inhibits the degradation of pRB
We next investigated whether MdmX stabilizes pRB.
pcDNA4/HisMax-RB-RI was transiently transfected with or
without 3· FLAG-MdmX in 293 cells (Fig. 2). In the absence
of MdmX, the pRB level was reduced to 16.1% (83.9% reduc-
tion) by the treatment of cycloheximide (CHX) for 10 h. How-
ever, pRB levels in both CHX-untreated and treated cells were
increased by co-expression of MdmX. Importantly, MdmX
inhibited the reduction in the pRB level in the presence of
CHX (61.1% reduction). These results indicate that MdmX
can inhibit degradation of pRB and stabilize pRB in cells.
3.3. MdmX binds to pRB and inhibits the interaction between
pRB and Mdm2
To elucidate the mechanism by which MdmX inhibits
Mdm2-meditated pRB ubiquitination and degradation, we
examined the ability of MdmX to bind pRB. As shown inFig. 2. Degradation of pRB is inhibited by MdmX. (A) pcDNA4/
HisMax-RB-RI was transiently transfected with or without 3· FLAG-
MdmX into HEK293 cells. Thirty-eight hours after the transfection,
10 lg/ml cycloheximide (CHX) was added to the medium and the
culture was continued for another 10 h. Lysates from CHX-untreated
(0 h) and treated (10 h) cells were subjected to IB using the indicated
antibodies. (B) RB-RI protein levels were normalized to the Hsp90
level and the quantitative data are presented as the % values relative to
the MdmX-untransfected 0-time.Fig. 3A, endogenous pRB in U2OS cells and HCT116 cells
were co-immunoprecipitated with endogenous MdmX in these
cells. Furthermore, ectopically expressed MdmX was also able
to bind to both wild-type pRB and its C-terminal region (RB-
X/N, Fig. 1A) in HEK293 cells (Fig. 3B). These data indicate
that MdmX can interact with pRB in intact cells. Since we pre-
viously showed that the C-terminus of pRB is required for its
Mdm2-mediated ubiquitination and degradation via interac-
tion with Mdm2 [6], it is feasible that MdmX competes with
Mdm2 for binding to pRB. To test this hypothesis, we investi-
gated the eﬀects of MdmX overexpression on Mdm2 binding
to RB-X/N. When MdmX was transiently overexpressed, the
levels of Mdm2 associated with pRB-X/N in the immunopre-
cipitates were reduced in an MdmX dose-dependent manner
(Fig. 3C, lanes 4–6). The levels of co-immunoprecipitated
pRB-X/N were hardly aﬀected by MdmX overexpression.
The MdmX–pRB interaction was also observed in p53/
Mdm2/ MEFs (Fig. 3D), suggesting that MdmX can bind
to pRB not only via heterodimerization with Mdm2 but also
in an Mdm2-independent manner. In support of this,
MdmXDC was able to bind to the C-terminal region of pRB
(RB-X/N) (Fig. 3C, lane 8). Together, these results suggest that
MdmX and Mdm2 compete with each other for binding to
pRB. Although our ﬁndings in these transient expression
experiments in intact cells suggest that MdmX contributes to
pRB stabilization by competing with Mdm2 for binding to
pRB, diﬀerent mechanisms for regulation of pRB stability by
MdmX cannot be ruled out.
3.4. MdmX protein level regulates the level of pRB and its
function
Since MdmX has the ability to suppress Mdm2-mediated
ubiquitination of pRB, we examined whether downregulation
of MdmX in cells reduces the pRB protein level due to en-
hanced destabilization of pRB. For this purpose, U2OS cells
were transfected with either an MdmX siRNA (X) or a control
siRNA (C). As shown in Fig. 4A, the level of endogenous
MdmX protein was reduced by the MdmX siRNA. As ex-
pected, MdmX downregulation decreased the steady-state le-
vel of endogenous pRB, while the Mdm2 level was nearly
unaﬀected (data not shown). On the contrary, the p53 level
was slightly increased, which may be due to downregulation
of the ubiquitin ligase activity of Mdm2 against p53 following
MdmX ablation. Quantitative analyses revealed that the pRB
level in MdmX-ablated cells was signiﬁcantly reduced to 44%
(P < 0.005 by Fisher’s exact probability test) of the level in
control cells, while the p53 level was increased to 153%
(P < 0.05) of the control level (Fig. 4B).
To investigate the eﬀects of MdmX on pRB function, we
next performed a ﬂat cell formation assay using SRB1 cells.
Since we previously showed that wild-type Mdm2 inhibits
pRB-mediated ﬂat cell formation [6], we hypothesized that
MdmX was able to overcome the inhibition of pRB-mediated
ﬂat cell formation by Mdm2. SRB1-wt-Mdm2 cells were trea-
ted with a low dose of tetracycline (5 ng/ml) and then transfec-
ted with 3· FLAG-MdmX plasmids. As shown in Fig. 5A,
MdmX-positive cells (arrows) showed a signiﬁcantly altered
morphology to large ﬂat cells compared with MdmX-negative
cells (arrowheads) (76.4% vs. 8.3%, P < 0.0001 by Fisher’s ex-
act probability test; Fig. 5B). These results suggest that MdmX
overexpression restored pRB function by impeding Mdm2-
mediated inhibition of pRB function.
Fig. 3. MdmX binds to pRB and inhibits the interaction between pRB and Mdm2 (A) Interaction of endogenous pRB and MdmX. Exponentially
growing U2OS cells and HCT116 cells were treated with 10 lM MG132, a proteasome inhibitor, for 8 h. Cell lysates were subjected to
immunoprecipitation (IP) with a mixture of anti-MdmX monoclonal antibodies, 3G12 and 7C8 [15], or control IgG. The immunoprecipitates were
subjected to immunoblotting (IB) using an anti-pRB (G3–245) or anti-MdmX antibody (D-19). (B) Binding of MdmX to wild-type pRB (W) and its
C-terminal domain (X/N). Expression plasmids for the indicated proteins were transfected into HEK293 cells. Cell lysates were subjected to IP with a
control IgG or Omni-probe (Santa Cruz Biotechnology), an Xpress-tag-detectable polyclonal antibody directed against sequences mapped between a
His-tag and the multicloning site in the pcDNA4/HisMax vector. Coprecipitated pRB and MdmX were detected with Omni-probe and an anti-
FLAG antibody, respectively. Arrowheads: pRB; asterisk: non-speciﬁc bands. (C) Inhibition of the pRB–Mdm2 interaction by overexpression of
MdmX. Expression plasmids for the indicated proteins were transfected into HEK293 cells and cell lysates were subjected to IP of pRB with Omni-
probe. Coprecipitated pRB and Mdm2 or MdmX were detected with Omni-probe and an anti-FLAG antibody, respectively. Arrow: Mdm2; black
arrowhead: full-length MdmX; white arrowhead: MdmXDC. (D) Binding of pRB and MdmX in Mdm2-knockout MEFs. 3· FLAG-MdmX and
Xpress-pRB were coexpressed in p53/ Mdm2/ MEFs and subjected to IP with an anti-FLAG antibody (M2) and anti-pRB antibody,
respectively, or control IgG. Immunoprecipitates were subjected to IB with the indicated antibodies.
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function in another way, we performed a reporter gene expres-
sion assay using C/EBPb-luciferase. It has been known that
pRB inhibits the DNA-binding activity of C/EBPb and C/
EBPb-mediated transcriptional activation [17]. As shown in
Supplementary ﬁgure 1, co-transfection of MdmX shRNA
plasmid, which eﬀectively suppresses MdmX expression, en-
hanced the C/EBPb-mediated transactivation, indicating that
destabilization of pRB caused by MdmX downregulation pos-
itively regulate the C/EBPb activity. These results suggest that
endogenous MdmX aﬀects endogenous pRB function.4. Discussion
We recently reported that Mdm2 degrades pRB as well as
p53 via the ubiquitin-proteasome pathway [6]. Here, we have
shown that MdmX also functions as a negative regulator of
p53, similar to Mdm2, consistent with previous reports that
MdmX facilitates Mdm2-mediated ubiquitination and degra-
dation of p53 [13,14] while inhibiting p53-dependent transcrip-
tion [9]. In light of the signiﬁcant roles of Mdm2 in
tumorigenesis via abrogation of both the p53 and pRB path-
ways, we considered that it was also worthwhile to verify the
eﬀects of MdmX on Mdm2-mediated regulation of pRB func-
tion. Interestingly, we found that Mdm2-meditated ubiquitina-
tion of pRB was inhibited by MdmX. We hypothesized that
this inhibition may result in reduced degradation of pRB,
thereby increasing the pRB protein level. This idea was sup-ported by our ﬁndings that inactivation of endogenous MdmX
with an siRNA reduced the endogenous pRB level. In addi-
tion, MdmX inhibited degradation of pRB in ectopic expres-
sion system. Moreover, overexpression of MdmX in SRB1
cells expressing wild-type Mdm2 restored the cells to a ﬂat
morphology, indicating that the enhanced MdmX levels stabi-
lized pRB and restored its functions.
The ﬁnding that MdmX inhibited pRB ubiquitination
prompted us to investigate whether MdmX prevents Mdm2
from interacting with pRB. Immunoprecipitation analysis con-
ﬁrmed the interaction of endogenous pRB and MdmX.
Although our data indicated that MdmX could interfere with
the pRB–Mdm2 interaction by competing with Mdm2 for
binding to the C-terminal domain of pRB, the precise mecha-
nism by which MdmX diﬀerentially regulates the Mdm2-med-
iated downregulation of p53 and pRB has not yet been
determined. MdmX and Mdm2 share binding to the N-termi-
nus of p53, which is also required for the Mdm2-independent
inhibition of p53 activity by MdmX. We found that the
RING-ﬁnger domain of MdmX was necessary for facilitation
of the Mdm2-mediated ubiquitination of p53, as reported in
previous studies [14]. On the other hand, although both MdmX
and Mdm2 interact with the C-terminal region of pRB, MdmX
inhibits Mdm2-mediated pRB ubiquitination. In addition, the
RING-ﬁnger domain is not required for suppression of
Mdm2-mediated pRB ubiquitination, since MdmXDC retains
the ability to inhibit pRB ubiquitination. These ﬁndings indi-
cate that MdmX needs to heterodimerize with Mdm2 via the
RING-ﬁnger domain in order to have an eﬀect on p53 ubiqui-
Fig. 5. MdmX positively regulates the pRB function. Mdm2-mediated
inhibition of ﬂat cell formation is released by MdmX. (A) SRB1 cells
expressing wild-type Mdm2 were treated with a low dose of tetracy-
cline (5 ng/ml) and then transfected with 3· FLAG-MdmX expression
plasmids. At 7 d after the transfection, the cells were immunostained
with an anti-FLAG antibody (green). Arrows: ﬂat cells; arrowheads:
non-ﬂat cells. (B) The histogram shows the ratios of ﬂat cells among
the MdmX-negative and MdmX-positive wild-type Mdm2-expressing
SRB1 cells.
Fig. 4. MdmX positively regulates the pRB level. (A) Endogenous
pRB expression is suppressed by knockdown of MdmX. U2OS cells
were transiently transfected with an siRNA for MdmX (X) or control
siRNA (C), and the indicated protein expression levels were analyzed
by immunoblotting. (B) The MdmX, pRB and p53 protein levels were
normalized to the a-tubulin level and the quantitative data are
presented as the % values relative to the control siRNA. The
means ± S.E. of six separate experiments are shown. *P < 0.005,
**P < 0.05.
C. Uchida et al. / FEBS Letters 580 (2006) 1753–1758 1757tination, but not on pRB ubiquitination. An adequate balance
of the expression levels of Mdm2,MdmX, pRB and p53 may be
critical for the regulation of Mdm2-mediated ubiquitination of
pRB and p53 by MdmX. Further investigations are required to
elucidate the mechanism of the distinct functions of MdmX. It
is interesting that Mdm2 promotes degradation of pRB via
both ubiquitin-dependent [6] and independent pathways [7].
Our ﬁndings in the present study indicate that MdmX can sta-
bilize pRB by competing with Mdm2 for binding to pRB. It is
likely that MdmX could also inhibit ubiquitin-independent
degradation of pRB by competing with Mdm2.
Another question that arises is the biological signiﬁcance of
the eﬀect of MdmX on the Mdm2-mediated downregulation
of pRB. MdmX-knockout mice die in the early embryonic
stage, and can be rescued in a p53-null background [18–20].
Several studies have implicated MdmX in tumor formation,
similar to the case for Mdm2. Overexpression of MdmX can
transform cultured cells [21]. Furthermore, signiﬁcant overex-
pression of the MdmX protein and mRNA, which can be ex-
plained by gene ampliﬁcation, has been observed in several
tumor types, including breast cancers [22]. These reports
strongly suggest that MdmX is an oncogene product. MdmX
may play diﬀerent roles in the p53 and pRB pathways as a mod-
ulator to diﬀerentially regulate the cell cycle, cell diﬀerentiation,
apoptosis and carcinogenesis. In some tumors, the excess level
of MdmX may facilitate not only the Mdm2-mediated p53
degradation thereby inhibiting apoptosis but also the pRB-
mediated inhibition of apoptosis and accelerate cell prolifera-
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